Table 3.

Treatment characteristics within 12-month follow-up

Eyes treated, n (%)	155 (62.2)
Macular laser, n (%)	39 (25.1)
Anti-VEGF therapy, n (%)	136 (88.9)
Anti-VEGF therapy only, n (%)	107 (69.9)
No. of anti-VEGF injections, mean (SD)	4.7 (2.6)
No. of ranibizumab injections, mean (SD)	3.0 (2.7)
No. of aflibercept injections, mean (SD)	0.9 (2.2)
No. of bevacizumab injections, mean (SD)	0.8 (2.0)
Triamcinolone acetonide, n (%)	1 (0.7)
No. of triamcinolone acetonide injections, mean (SD)	1.0 (0.0)
DEX implant, n (%)	8 (5.2)
No. of DEX implants, mean (SD)	1.0 (0.0)
Additional treatment, n (%)
Panretinal photocoagulation	32/249 (12.9)
Conduction of cataract surgery	12/207 (5.8)

DEX dexamethasone, SD standard deviation, VEGF vascular endothelial growth factor